Protean BioDiganostics Inc
Protean BioDiagnostics is a cancer diagnostics company focused on improving access to precision cancer diagnostics for all patients, regardless of their location. They offer a proprietary cancer profiling system called Protean MAPS®, which incorporates high-quality tests to deliver rapid results for all cancer types. Their services provide decision support and precision oncology guidance, along with telemedicine and virtual tumor boards featuring AI clinical trial matching. The company aims to support community-based cancer patients and their doctors by making advanced tissue and blood diagnostics accessible, thereby enabling the effective use of targeted therapy and immune-based therapies.
Protean BioDiganostics Inc
Protean BioDiagnostics is a cancer diagnostics company focused on improving access to precision cancer diagnostics for all patients, regardless of their location. They offer a proprietary cancer profiling system called Protean MAPS®, which incorporates high-quality tests to deliver rapid results for all cancer types. Their services provide decision support and precision oncology guidance, along with telemedicine and virtual tumor boards featuring AI clinical trial matching. The company aims to support community-based cancer patients and their doctors by making advanced tissue and blood diagnostics accessible, thereby enabling the effective use of targeted therapy and immune-based therapies.
TL;DR
Headquarters: Orlando, Florida
Founded: 2017
Core product: Protean MAPS — integrated cancer profiling, decision-support and telemedicine platform
Lab accreditations: CLIA-certified, CAP-accredited
Funding status: Seed round reported; total disclosed funding $330,000 (USD) with last public date 2019-06-26
Company Overview
Problem Domain
Precision oncology diagnostics and decision-support for cancer care across community and hospital settings.
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
330000
Last funding date recorded on profile; public profile lists Seed as last round
Investor Signal
“Company advertises a limited-time investment opportunity for current investors and states it is cash-flow positive with projected near-term revenue”